The MHC region on chromosome 6 contains a large number of non-HLA genes next to the HLA genes. Matching for HLA in unrelated hematopoietic SCT (HSCT) does not necessarily mean that these non-HLA genes are also matched. We selected 348 Northwest European patients transplanted with an HLA-A-, -B-, -C-, -DRB1-, -DQB1-matched unrelated donor (MUD) between 1987 and 2008. Patients' haplotypes were identified via descend. We were unable to determine the haplotypes of the donor; therefore we used frequent haplotypes (FH) in high linkage disequilibrium (LD) as a proxy for haplotype matching. Presence of a FH in a patient positively affected the probability and speed of identifying a matched unrelated donor. Competing risk survival analysis showed that patients with one or two FH have a statistically significantly decreased probability of developing Xgrade II acute GVDH (aGVHD) without increased risk of relapse compared to patients without FH (HR (95% CI): 0.53 (0.31-0.91)). This association was strongest for those FH with the highest LD between both HLA-A and -C or -B, and HLA-C or -B and -DRB1 (HR (95% CI): 0.49 (0.26-0.92)). These results extend evidence that non-HLA allele coding regions have a significant impact on development of Xgrade II aGVHD. We conclude that there is more to successful HSCT than matching for HLA genes.
INTRODUCTION
Acute GVHD (aGVHD) is a major cause of mortality following unrelated hematopoietic SCT (HSCT). Even in patients transplanted with a 10/10 allele level typed HLA-matched unrelated donor (UD) the incidence of aGVHD may still be significant. 1 This indicates that not only classical HLA antigen mismatches are responsible for the development of aGVHD. The MHC region on chromosome 6 is one of the most densely gene-packed segments of the human genome and contains a large number of non-HLA genes which spread across the entire class II, class III and class I segments. 2 In 10/10 HLA-matched unrelated donor-patient pairs there is no certainty that these non-HLA genes are also matched, because these matched pairs do not necessarily share the same haplotypes. The biological impact of HLA haplotype matching for HSCT has not been explored as extensively as that of matching for HLA alleles or loci. Matching for the HLA-B, -C and HLA-DR, -DQ haplotype blocks, 3 and more recently, matching for HLA-A, -B, -DR haplotypes 4 within 10/10 HLA-matched unrelated donor-patient pairs is associated with less post transplantation complications. Furthermore, Japanese patients having one of three most frequent haplotypes (FH) were found to have differential risk of developing aGVHD. It appeared that the genetic factor of specific haplotypes is associated with either increased or decreased risk of aGVHD. 5 The role of some of these non-HLA genes have been studied (reviewed [6] [7] [8] [9] [10] ): single nucleotide polymorphisms and/or microsatellites within cytokine (-receptor) genes and other non-HLA encoded genes, including those of the innate immune system, may indeed influence HSCT outcome. [11] [12] [13] [14] [15] [16] [17] Genes in the TNF block, MICA/MICB and microsatellite markers are of specific interest because they are in linkage disequilibrium (LD) with the classical HLA genes and could be inherited together as one genetic unit. [13] [14] [15] [18] [19] [20] [21] The presence of FH in patients also affects the probability and speed of identifying a matched UD. [22] [23] [24] [25] [26] [27] [28] It is essential to know the HLA distribution of each population at an allelic level in order to define whether a patient has a high or low probability of finding a matched donor. 27 Our group has previously shown that 30% of Northwest European patients became medically unfit during the search process and therefore did not receive a HSCT (which was unrelated to donor availability). Search time was identified as the most crucial factor in the UD search. 29 The aim of this study was therefore to identify the most frequent 5 locus allele level typed HLA haplotypes in the Dutch population and to elucidate the effect of frequency and LD of the patients' HLA haplotypes on donor search and clinical outcome of unrelated HSCT.
PATIENTS AND METHODS
HLA genotyping, HLA-haplotypes and LD level retrospectively. Because we were unable to determine the haplotypes of the donor, we used FH in high LD as a proxy for haplotype matching. Patients were divided into three groups; patients with two FH, patients with one FH and patients with no FH. Frequent 5 locus HLA-haplotypes were defined as haplotypes that occur with a frequency of 41% in the Dutch population (Table 1) .
Maximum-likelihood haplotype frequencies were estimated using an expectation-maximization algorithm 30 in 975 high-resolution HLA-typed Dutch leukemia patients. We also tested if the genotypes in this sample were present in the expected Hardy-Weinberg proportions. The classical LD coefficient measuring deviation from random association between alleles at different loci is delta (D). 31 D is the absolute measure of LD; it is defined by the difference between the observed haplotype frequency and the haplotype frequency that would be expected from the genotype frequency of the alleles in the haplotype, in the absence of LD. We calculated the D for the 5 locus haplotypes and also for all possible 2 locus haplotypes. These analyses were performed using the Pypop program. 32 Donor search UD search data were collected from the search database and the patients' charts at Europdonor Foundation. Start date of the search was defined as the date a patient was registered for an UD search at Europdonor Foundation. Each search was individually reviewed; there are no fixed time scales in which a search has to be completed. The first donor tested and considered to be acceptable for transplantation was defined as an 'acceptable donor', these included 9/10 HLA-mismatched and 10/10 HLAmatched donors (HLA-A, -B, -C, -DRB1, -DQB1). For 29 (7%) patients the search successfully continued for a 10/10 HLA-matched donor. Therefore we made a distinction between dates an 'acceptable donor' or a 10/10 HLA-matched donor was found and performed the analysis on these two groups separately.
Patient population
For this study we have used two different cohorts; one to investigate the impact of FH on the UD search (UD search analysis), and the other to investigate the impact of FH on transplantation outcome (transplantation analysis).
UD searches performed at Europdonor Foundation between 1987 and 2008 for Northwest European patients, both pediatric and adult, treated at LUMC were selected (n ¼ 580) for the UD search analysis. For 492 patients haplotypes could be derived by descent. Forty patients eventually underwent autologous transplantation and seven patients were transplanted with a cord blood unit; these patients were excluded from the study (n ¼ 47). Patients for whom intention for treatment was revoked for reasons not related to the search process were excluded from the study as well (n ¼ 44). Reasons included: transferral to a different transplant center (n ¼ 3), indication for transplantation changed (n ¼ 18), different therapy was chosen (n ¼ 4), withdrawal by the patient (n ¼ 8) and patient not reaching CR during the search (n ¼ 11). Finally, eight patients were excluded from the study because one or more HLA loci, other than DPB1, were not typed. In five patients the C locus was not typed, in one patient the DQ locus was not typed and in two patients both C and DQ loci were not typed. The remaining 393 patients formed the study population, both pediatric and adult. The excluded cohort was not statistically significantly different from the selected cohort (data not shown). Patient, search and HSCT characteristics of the UD search analysis are listed in Table 2 .
To study transplantation outcome we only selected patients who had been transplanted with a 10/10 HLA-matched UD. Because not all searches resulted in a HSCT we contacted two other transplant centers in the Netherlands (Erasmus MC and UMCU) and included their patients in order to reach sufficient numbers. The selected cohort for the transplantation analysis consists of 348 Northwest European patients, both pediatric and adult. Patients had known haplotypes derived from pedigree typing and were transplanted with a 10/10 HLA-A-, -B, -C-, -DRB1-, -DQB1-matched UD. The patients were treated at three Dutch HSCT centers (LUMC, Erasmus MC and UMCU) and UD originated from national or international donor registries. Clinical patient information was made available by the HOVON Data Center from the EBMT (European group for Blood and Marrow Transplantation) patient database. Patient, donor and transplantation characteristics of the transplantation analysis are listed in Table 3 .
Endpoints and competing risks
Primary endpoint for the UD search analysis was the conclusion that no 'acceptable donor' was found (9/10 HLA mismatched or 10/10 HLA matched). Patients were censored at the date a donor was found. Death or deterioration of the clinical condition before a donor was found was considered to be a competing risk. Primary endpoint for the transplantation analysis was the incidence of Xgrade II aGVHD. Peak severity of aGVHD after HSCT defined according to grade (no (n ¼ 172), I (n ¼ 85), II (n ¼ 41), III (n ¼ 13) or IV (n ¼ 7)) was available for 322 patients. The number of patients with grade III and IV (n ¼ 20) was too small to perform a meaningful analysis. Patients were censored at date of DLI, relapse or second HSCT within 100 days after HSCT and also at 100 days after HSCT. Death without Xgrade II aGVHD within 100 days after HSCT was treated as a competing risk.
Secondary outcomes in the transplantation analysis were mortality and relapse incidence. For 347 patients cause of death was available, for the relapse analysis only patients with malignant diseases (n ¼ 290) were included. Patients were censored at date of DLI or second HSCT and those who survived were censored at time of last contact. Looking at relapse, death without relapse was defined as competing risk.
Statistical analysis
We investigated the incidence of not finding a 9/10 HLA-mismatched or 10/10 HLA-matched UD (UD search analysis) and the incidence of Xgrade II aGVHD, relapse and mortality (transplantation analysis) in relation to the number of FH of the patient. FH were categorized into three groups based on LD between the HLA-A and -C or -B loci, the HLA-C or -B and -DRB1 loci or both parts, and also investigated the association with the three different transplantation endpoints. In all analyses the group without FH was set as reference. Table 1 . Differences in patient-, search-, donor-and transplantation-related characteristics between 0, 1 or 2 FH were examined with Pearson's w 2 test or Fishers' exact test for discrete variables and Kruskal-Wallis test for continuous variables. Hazard ratios (HR), 95% confidence intervals (95% CI) and P-values were obtained using the proportional hazards model for the subdistribution of competing risks of Fine and Gray 33 to quantify the influence of FH on the UD search results and the different transplantation endpoints.
Patient-, search-, donor-and transplantation-related characteristics that were associated with both number of FH and UD search results or transplantation endpoints were considered as potential confounding variables in our data sets. These were evaluated for each endpoint separately and identified as confounding variables when including them in the model (one by one), the crude association (b estimate) changed by 410%. For UD search models none of the variables were identified to confound the association. For Xgrade II aGVHD models, patient age (continuous), Campath use (yes/no) and conditioning (myeloablative/ reduced intensity) were identified. For mortality models, donor age (continuous), HSCT year (continuous), ABO match (yes/no), CMV match (negative donor to positive patient), disease type (myeloid/lymphoid malignancy/non-malignant), T-cell depletion (TCD) of the graft (yes/no), Campath use (yes/no), disease status at HSCT (first CR or chronic phase and non-malignant/other) and conditioning (myeloablative/reduced intensity) were identified. For relapse models, gender match (female donor to male patient/other), CMV match (negative donor to positive patient), disease type (myeloid/lymphoid malignancy/non-malignant), ATG use (yes/no), Ciclosporin use (yes/no), Campath use (yes/no), donor age (continuous) and conditioning type (myeloablative/reduced intensity) were identified. All identified confounding variables were included in the multivariate models to adjust for confounding.
Two-sided P-values p0.05 were considered statistically significant. Statistical analysis was performed using SPSS 19.0 for Windows (IBM) and the CMPRSK package in R version 2.14.1 (open source).
RESULTS
The most frequent five locus allele level typed HLA haplotypes found in the Dutch population are represented in Table 1 . These frequencies were comparable to other Northwest European populations and the genotypes in the sample showed no evidence of significant deviation from Hardy-Weinberg equilibrium.
In the UD search cohort, patients with or without FH were similar with regard to gender, age, diagnosis, search period, urgent searches and reasons for not reaching transplantation (Table 2) . Of the 393 UD searches evaluated 311 (79%) were successful, either a 9/10 HLA-mismatched or 10/10 HLA-matched donor was found. For 82 (21%) patients the UD search was not successful; for 56 (14%) patients no donor was found and 26 (7%) patients died before a donor was found or because of deterioration of their clinical condition during the search. Of 393 patients 148 (38%) had one or two FH. For those patients a donor was found more often in a shorter time period compared to patients without FH. As a consequence, patients with one or two FH were transplanted more often (Table 2) . Cumulative incidence curves show that in both groups (acceptable and 10/10-matched donors) for the patients with two FH always a donor was found (indicating the flat line); this is after correction for competing risks (deterioration of the patients' condition or death). For patients with one FH there still is increased success in finding an acceptable donor; however the effect on finding a 10/10 matched donor is less strong. As expected, for the group of patients without FH, a low probability of finding a suitable donor is shown (Table 2 and Figure 1) .
Looking at the transplantation cohort, patients with and without FH were statistically significantly dissimilar only with regard to donor age at transplantation. Patients with one or two FH generally have more potential donors to choose from compared to patients without FH, therefore the younger donors are selected for transplantation more often (Table 3) . Competing risk survival analysis, after correction for confounding variables, showed that patients with one or two FH had a statistically significant decreased probability of developing Xgrade II aGVHD without an increased risk of relapse compared to patients without FH (HR (95% CI): 0.53 (0.31-0.91)) ( Figure 2 and Table 4 ). This Table 4 ). We did not observe an effect on incidence of mortality in any analyses performed (Figures 2 and 3 and Table 4 ).
DISCUSSION
Our UD search results as well as results published by Pedron et al. 25 demonstrate that at time of UD search initiation, knowledge of FH in our own but also other countries may be used to develop strategies to optimize UD searches and help physicians to organize patient care strategies. HLA genotype frequency and/or haplotype frequency can be used for the estimation of the probability that a haplotypically identical UD for an individual patient can be found. 34 So, if there are multiple 10/10 HLA-matched UD available for a certain patient, the search coordinator might want to look at registries with similar haplotype distribution to the patient, increasing the likelihood of haplotype matching on top of HLA matching. Furthermore, for patients with less frequent HLA gene combinations of haplotype frequencies requesting more donor blood samples for complementary typing at the start of the search seems reasonable in order to decrease the delay in finding an UD. 23 In our cohort the number of patients with one or two FH was substantial (38%); therefore the effect of using HLA haplotypes in UD searches can be very relevant.
Our transplantation results are in concordance with results from Petersdorf et al. 4 and the Japanese study, 5 showing less Xgrade II aGVHD in the patients with FH. Although there are genetic differences between our population and the Japanese population, the principle appears to be similar. Because the patients and donors had identical HLA-A, -B, -C, -DRB1 and -DQB1 alleles, Xgrade II aGVHD could not have been caused by differences in these HLA genes, which supports the idea that within the MHC additional genes that encode transplantation antigens are present and/or regulate the immune response to minor transplantation antigens. Patients with FH in highest LD between both HLA-A and -C or -B, and HLA-C or -B and -DRB1 had the lowest incidence of Xgrade II aGVHD suggesting that these additional genes might be located both telomeric and centromeric to HLA-B. Although our analysis demonstrated no difference in OS, the decreased risk of Xgrade II aGVHD is important to note. Research showing that quality of life is negatively impacted by aGVHD 35 and health care costs are significantly higher with the development of aGVHD 36 indicate the importance of reducing aGVHD. (25) 14 (33) 102 (29) Female (D) to male (P), n (%)
32 (20) 20 (14) 5 (12) 57 (16) (18) 20 (14) 4 (9) 52 (15) -Plasma cell disorder 11 (7) 6 (4) 4 (9) 21 (6) -MDS/MPS 13 (8) 18 (12) 9 (21) 40 (12) -BM failure 11 (7) 12 (8) 6 (14) 29 (8) Inherited disorder 13 (8) 11 (8) 3 (7) 27 (8) Onset of aGVHD might not depend only on non-HLA gene matching between donor and patient, but also on immune regulation possibly affected by the presence of a certain single nucleotide polymorphism in cytokine encoding genes within the MHC region in either patient or donor. Next to the previously mentioned genetic variants of TNF, MICA/MICB and microsatellite markers many other genes have the potential to influence immune functions or lead to different susceptibility to aGVHD such as TAP1/TAP2 and LMP2/LMP7 genes, complement and the heat shock proteins. Immunogenetic profiles for successfully transplanted individuals including parameters as HLA haplotypes and cytokine gene polymorphism may contribute to a better understanding of the underlying mechanisms leading to aGVHD. 9 Morishima et al. 5 demonstrated that the HLA haplotype itself affects incidence of aGVHD. These findings suggest that the genetic factor of specific haplotypes would contribute to reducing or increasing the risk of aGVHD. In HSCT, aGVHD has been known to result mainly from donor T cells recognizing minor histocompatibility antigens presented on HLA molecules of a recipient's organs. 37 HLA alleles in each haplotype might present different immunodominant peptides to T cells and give rise to different alloreactivity in HLA-matched UD HSCT. Furthermore, HLA-DR15-positive patients transplanted from HLA-matched donors have shown a reduced incidence of aGVHD for HLA-DR15-positive patients transplanted from HLA-matched donors. 38 The most frequent five-locus allele level-typed HLA haplotypes found in the Dutch population were comparable to other Northwest European populations. The sample population was in Hardy-Weinberg equilibrium; therefore, we conclude the sample was free from selection bias and was large enough to estimate reliable haplotypes from. Another major strength of our analysis is that we used competing risk analysis in both UD search and transplantation analysis preventing overestimated estimates. Because we used FH as a proxy for HLA haplotype matching, there is a certain margin of error in the transplantation analysis, we suspect that the actual association might be even stronger. Many variables could have confounded our results; we chose to check every variable for every end point separately and see whether they influenced transplantation outcome in our study population. For patients with one or two FH more often younger donors were found and donor age was statistically significantly different in the three FH groups. Donor age was previously identified to influence transplantation outcome; 39 we included it in the mortality and relapse model to correct for confounding (after testing). Time to transplant 29 also could have been a potential confounder, because patients with one or two FH had shorter UD search times. However, time from diagnosis to transplantation was not different in the three FH groups and was not identified as a confounding variable in our data. The use of BM versus PBSC was borderline statistically significant different in the three FH groups, patient with 1 or 2 FH more often received a BM graft. Additionally, these patients were more often pediatric patients. This could have potentially influenced the lower aGVHD rates we saw in patients with 1 or 2 FH. 40 Use of BM was not identified as a confounding factor in our population, but we did correct for patient age in the aGVHD model. DPB1 matches were not identified as a confounding factor in any of the analyses and therefore, did not influence our results. 41 We believe we have dealt with possible confounding from these variables in the appropriate way. The use of the classical D for quantifying LD may constitute a potential weakness in our analysis, because the D calculations are probably only an estimation of the true LD. Furthermore, because the D is linked to the genotype frequency it is difficult to compare the D between haplotypes with different frequencies. More elaborate calculations are available, but they are not always possible to calculate or easier to interpret, especially when applied to 5 locus haplotypes. Also, the categorization into three groups (HLA-A and -C or -B loci, HLA-C or -B and -DRB1 loci, or both parts) was based on the LD. Patients with and without FH were similar in receiving TCD, however the methods used for TCD were very heterogeneous. Because of this heterogeneity we were unable to clearly elucidate the effect of TCD on the association between FH and XgradeII aGVHD, which could have influenced our results. Regardless of these flaws; we believe the results still have meaningful value.
Our results confirm and extend evidence that there are non-HLA gene-coding regions within the MHC that have a significant impact on transplantation related complications, in particular the incidence of Xgrade II aGVHD. We conclude that there is more to successful HSCT than matching for classical HLA class I and II genes. Table 4 . Table 4 .
